Merck Prostate 365 - Combination therapies for mCRPC (Prostate Cancer)
What is the Purpose of this Study?
If you choose to join this study, you will:
- Be assigned to take the study drug, pembrolizumab, in combination with lenvatinib, or MK-7684, or carboplatin + etoposide
- Have blood draws
- Give urine samples
- Have imaging scans (CT and/or MRI)
Pembrolizumab, MK-7684, etoposide, and carboplatin are all drugs taken intravenously (through a needle in a vein in your arm). Lenvatinib is a pill that you take by mouth.
Metastatic Castrate-Resistant Prostate Cancer
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with a type of metastatic castrate-resistant prostate cancer called "neuroendocrine carcinoma"
- Have previously been treated with a drug called docetaxel
For more information about who can join this study, please contact the study team at julia.hurrelbrink@duke.edu
What is Involved?
We are doing this study to find out if the study drug, pembrolizumab, is a safe and effective treatment for metastatic castrate-resistant prostate cancer when it is given in different combinations with other drugs. Pembrolizumab may work by increasing your immune system's response against a tumor.
Study Details
